Article Text

Download PDFPDF
Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin
  1. Dmitri Wall1,
  2. Mairín McMenamin2,
  3. Deirdre O'Mahony3,
  4. Alan D Irvine1,4
  1. 1Department of Dermatology, St James's Hospital, Dublin, Ireland
  2. 2Department of Pathology, St James's Hospital, Dublin, Ireland
  3. 3Department of Oncology, St James's Hospital, Dublin, Ireland
  4. 4Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
  1. Correspondence to Professor Alan D Irvine, irvinea{at}tcd.ie

Summary

There are four clinical subtypes of Kaposi sarcoma (KS): classic, endemic, epidemic and iatrogenic. The geographical prevalence of the endemic variant matches areas of human herpes virus type 8 (HHV8) seroprevalence. The iatrogenic variant, seen in immunosuppressed patients, can be associated with significant morbidity and mortality. This is the first report of KS described in the context of atopic dermatitis (AD) treated with ciclosporin (CSA). We report a case of KS in an HHV8 seropositive Congolese patient following immunosuppression with CSA for AD. Treatment has been challenging, protracted and associated with significant morbidity. Immunosuppressive therapies are increasingly used for inflammatory dermatological conditions, including AD. This case highlights the importance of HHV8 screening of patients from endemic regions or those with other risk factors. It also highlights the importance of early recognition of a condition associated with significant morbidity and even mortality to facilitate appropriate treatment.

View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.